HUTCHMED DRC is a drug manufacturers - specialty & generic business based in the US. HUTCHMED DRC shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $16.74 – a decrease of 6.74% over the previous week. HUTCHMED DRC employs 1,970 staff and has a trailing 12-month revenue of around $610.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $16.74 |
|---|---|
| 52-week range | $11.93 - $21.92 |
| 50-day moving average | $18.74 |
| 200-day moving average | $17.84 |
| Wall St. target price | $28.53 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16.74 from 2024-11-15
| 1 week (2024-11-08) | -6.74% |
|---|---|
| 1 month (2024-10-17) | -13.80% |
| 3 months (2024-08-16) | -9.37% |
| 6 months (2024-05-17) | -17.01% |
| 1 year (2023-11-17) | -10.10% |
|---|---|
| 2 years (2022-11-17) | 49.60% |
| 3 years (2021-11-17) | 31.19 |
| 5 years (2019-11-15) | 23.28 |
| Revenue TTM | $610.8 million |
|---|---|
| Gross profit TTM | $-271,587,000 |
| Return on assets TTM | -5.9% |
| Return on equity TTM | -5.44% |
| Profit margin | -6.87% |
| Book value | $0.87 |
| Market Capitalization | $2.9 billion |
TTM: trailing 12 months
We're not expecting HUTCHMED DRC to pay a dividend over the next 12 months.
HUTCHMED DRC's shares were split on 29 May 2019 .
Over the last 12 months, HUTCHMED DRC's shares have ranged in value from as little as $11.9343 up to $21.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while HUTCHMED DRC's is 0.746. This would suggest that HUTCHMED DRC's shares are less volatile than average (for this exchange).
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd. , Inmagene Biopharmaceuticals Co. Ltd.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.